#cell-therapy-manufacturing

[ follow ]
#biotherapeutics #commercial-growth #fda-approved-therapeutics #competitive-moat #ai-in-biotech #car-t
Venture
from24/7 Wall St.
2 days ago

Iovance Surged 44% This Week and Its Philadelphia Factory Explains Why

Iovance Biotherapeutics transformed from a pipeline company to a profitable commercial entity with proprietary manufacturing capabilities, driving a 43% stock surge after Q4 2025 earnings.
Healthcare
fromFortune
2 months ago

This U.K. startup's AI platform could slash the cost of CAR-T therapy and other cell-based medicines | Fortune

AI predicts future health and performance of human cells from microscope images, enabling selection of optimal cells and reducing cost and waste in cell-based therapies.
[ Load more ]